These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 32886306)
1. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor. Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T Hum Cell; 2021 Jan; 34(1):254-259. PubMed ID: 32886306 [TBL] [Abstract][Full Text] [Related]
2. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. Baldi GG; Gronchi A; Stacchiotti S Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598 [TBL] [Abstract][Full Text] [Related]
3. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor. Tap WD; Healey JH Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356 [TBL] [Abstract][Full Text] [Related]
4. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee? Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874 [TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of NCC-LMS2-C1-a novel patient-derived cancer cell line of leiomyosarcoma. Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T Hum Cell; 2021 Jan; 34(1):279-288. PubMed ID: 33001379 [TBL] [Abstract][Full Text] [Related]
7. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors. Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468 [TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T Hum Cell; 2020 Oct; 33(4):1321-1328. PubMed ID: 32815117 [TBL] [Abstract][Full Text] [Related]
10. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. Palmerini E; Longhi A; Donati DM; Staals EL Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819 [TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158 [TBL] [Abstract][Full Text] [Related]
12. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095 [TBL] [Abstract][Full Text] [Related]
13. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111 [TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Kito F; Oyama R; Sakumoto M; Shiozawa K; Qiao Z; Toki S; Yoshida A; Kawai A; Kondo T Hum Cell; 2019 Apr; 32(2):214-222. PubMed ID: 30737712 [TBL] [Abstract][Full Text] [Related]
15. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol. Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433 [TBL] [Abstract][Full Text] [Related]
16. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors. Thangaiah JJ; Koepplin JW; Folpe AL Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245 [TBL] [Abstract][Full Text] [Related]
17. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel Mejbel H; Siegal GP; Wei S Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489 [TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T Hum Cell; 2021 Jan; 34(1):246-253. PubMed ID: 32870449 [TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma. Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T Hum Cell; 2021 Mar; 34(2):688-697. PubMed ID: 33205363 [TBL] [Abstract][Full Text] [Related]
20. A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor. Lipplaa A; Meijer D; van de Sande MAJ; Gelderblom H; Bovée JVMG; Mei H; Szuhai K Genes Chromosomes Cancer; 2023 Apr; 62(4):223-230. PubMed ID: 36504457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]